<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03731364</url>
  </required_header>
  <id_info>
    <org_study_id>CA-PS-203</org_study_id>
    <nct_id>NCT03731364</nct_id>
  </id_info>
  <brief_title>Pain Study in Total Knee Arthroplasty</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Placebo-Controlled Efficacy, Pharmacokinetics and Safety Study of CA-008 in Subjects Undergoing Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Concentric Analgesics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Concentric Analgesics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled, parallel&#xD;
      design study of CA-008 vs. placebo injected/instilled during an elective TKA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled, parallel&#xD;
      design study evaluating, in a pilot stage of the study, up to 3 ascending dose level cohorts&#xD;
      each evaluating a single dose of CA-008 vs. placebo injected/instilled during an elective&#xD;
      TKA. Up to 54 subjects will be randomized in the pilot stage. During the second stage of the&#xD;
      study, subjects will be randomized to one of either 2 or 3 CA-008 dose levels (to be&#xD;
      determined) or placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 29, 2018</start_date>
  <completion_date type="Actual">May 31, 2019</completion_date>
  <primary_completion_date type="Actual">April 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-specific mean pain intensity scores (NRS) at Time 96 hours for CA-008 vs. placebo</measure>
    <time_frame>At 96 hours</time_frame>
    <description>Primary Efficacy Endpoint for the Pilot Stage. Time-specific mean pain intensity scores at Time 96 hours for CA-008 vs. placebo based on a 10 point numerical rating scale (NRS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CA-008 dose vs. placebo comparison: Area Under the Curve (AUC) 0 to 96 hours</measure>
    <time_frame>From 0 hours to 96 hours</time_frame>
    <description>Primary Efficacy Endpoint for Stage 2. Area Under the Curve (AUC) of the NRS current pain intensity scores from Time 0 hours to 96 hours at rest (AUC0 to 96h)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weighted sum of pain intensity (SPI) assessments</measure>
    <time_frame>Time 0 hours to 96 hours at rest (AUC0 to 96 hours)</time_frame>
    <description>For each CA-008 dose vs. placebo comparison the weighted sum of pain intensity (SPI) will be compared. Area Under the Curve (AUC) of the NRS current pain intensity scores from Time 0 hours to 96 hours at rest (AUC0 to 96 hours).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who do not require opioids (i.e., opioid free; OF)</measure>
    <time_frame>Time 0 hours to Time 96 hours: Opioid Free 0 to 96 hours</time_frame>
    <description>Key Secondary Efficacy Endpoints for Pilot Stage. For each CA-008 dose vs. placebo comparison: Percentage of subjects who do not require opioid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total opioid consumption (OC) (in daily oral morphine equivalents)</measure>
    <time_frame>Time 0 hours to Time 96 hours: OC 0 hours to 96 hours</time_frame>
    <description>Key Secondary Efficacy Endpoints for Pilot Stage. For each CA-008 dose vs. placebo comparison: Total opioid consumption (OC) (in daily oral morphine equivalents)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who do not require opioids</measure>
    <time_frame>Time 0 hours to Time 96 hours: Opioid Free 0 hours to 96 hours</time_frame>
    <description>Key Secondary Efficacy Endpoints for Stage 2. For each CA-008 dose vs. placebo comparison, percentage of subjects who do not require opioids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total opioid consumption (in daily oral morphine equivalents)</measure>
    <time_frame>OC from Time 0 hours to Time 96 hours: OC 0 hours to 96 hours</time_frame>
    <description>Key Secondary Efficacy Endpoints for Stage 2. For each CA-008 dose vs. placebo comparison, total opioid consumption (in daily oral morphine equivalents).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Using NRS at rest</measure>
    <time_frame>AUC 0 days to Week 1</time_frame>
    <description>Key Secondary Efficacy Endpoints for Stage 2. For each CA-008 dose vs. placebo comparison, using NRS at rest.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Acute Post-surgical Pain</condition>
  <arm_group>
    <arm_group_label>CA-008 - Pilot Stage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Pilot Stage</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CA-008</intervention_name>
    <description>5 mg in 100 mL 10 mg in 100 mL 15 mg in 100 mL</description>
    <arm_group_label>CA-008 - Pilot Stage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo in 100 mL</description>
    <arm_group_label>Placebo - Pilot Stage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Plan to undergo an elective primary unilateral total knee arthroplasty (TKA or knee&#xD;
             replacement), without collateral procedure or additional surgeries.&#xD;
&#xD;
          2. Be a reasonably healthy adult aged 18 - 80 years old, inclusive, with a BMI â‰¤ 36 kg/m2&#xD;
             and American Society of Anesthesiology (ASA) physical Class 1, 2 or 3 at the time of&#xD;
             randomization.&#xD;
&#xD;
          3. Males and females must abstain from intercourse, use acceptable birth control methods&#xD;
             or be sterile or otherwise incapable of having children.&#xD;
&#xD;
          4. Be willing and able to sign the informed consent form (ICF)&#xD;
&#xD;
          5. Be willing and able to complete study procedures and pain scales and to communicate&#xD;
             meaningfully in English. Be able and willing to return for outpatient follow up visits&#xD;
             as required.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. In the opinion of the Investigator,&#xD;
&#xD;
               1. have a concurrent painful condition, other than pain in the knee to be replaced,&#xD;
                  that may require pain treatment during the study period.&#xD;
&#xD;
               2. have active skin disease or other clinically significant abnormality at the&#xD;
                  anticipated site of surgery that could interfere with the planned surgery.&#xD;
&#xD;
          2. Have a known allergy to chili peppers, capsaicin or the components of CA-008,&#xD;
             ropivacaine, ketorolac, acetaminophen, fentanyl, hydromorphone, morphine or oxycodone.&#xD;
&#xD;
          3. Have significant medical, neuropsychiatric or other condition.&#xD;
&#xD;
          4. The following are considered disallowed medications:&#xD;
&#xD;
               1. tolerant to opioids as defined&#xD;
&#xD;
               2. capsaicin-containing products or foods.&#xD;
&#xD;
               3. central nervous system active agent as an analgesic adjunct medication&#xD;
&#xD;
               4. antiarrhythmics except beta-blockers, digoxin, warfarin, lithium, or&#xD;
                  aminoglycosides or other antibiotics for an infection&#xD;
&#xD;
               5. parenteral or oral corticosteroids.&#xD;
&#xD;
               6. antianginal, antihypertensive agent or diabetic regimen at a dose that has not&#xD;
                  been stable for at least 30 days or which is not expected to remain stable while&#xD;
                  participating in the study.&#xD;
&#xD;
          5. Have positive results on the alcohol breath/saliva test indicative of alcohol abuse or&#xD;
             urine drug screen indicative of illicit drug use at screening, and/or prior to&#xD;
             surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike Royal, MD</last_name>
    <role>Study Director</role>
    <affiliation>Concentric Analgesics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HD Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 24, 2018</study_first_submitted>
  <study_first_submitted_qc>November 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2018</study_first_posted>
  <disposition_first_submitted>June 3, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>June 3, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 5, 2020</disposition_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>August 18, 2021</submitted>
    <returned>September 15, 2021</returned>
    <submitted>November 9, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

